Sunday, 29 November 2020

Seagull BioSolutions gears up to prepare COVID-19 vaccine

14 April 2020 | News

The startup is being funded by the Department of Science and Technology (DST)

Image credit- shuttershock.com

Image credit- shuttershock.com

Seagull BioSolutions, a Pune based startup working on new biological technologies, is being funded by the Department of Science and Technology (DST), to undertake the development of Active Virosome (AV)-Vaccine and Immunodiagnostic kits for COVID-19 emergency.

Active Virosome Technology (AVT) is useful for the production of vaccines and immunotherapeutic agents. The AVT platform is useful for producing novel, non-hazardous & economical active virosome agents expressing desired antigens from the target pathogen. These will be used to develop a novel vaccine for the prevention of COVID-19 infection and also immunodiagnostic ELISA kits for COVID-19.

The immunodiagnostic kits are expected to be ready for field trials by the end of Aug 2020 and approved by the end of 10-11 months. On the other hand, the AV vaccine is expected to take a longer time. However, given the emergency situation, the startup aims to complete the proof of concept in 80 days & complete preclinical development & start Phase I trial by the end of 18-20 months.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls